Mdxhealth SA

MDxHealth officer Joseph Sollee was granted 237,100 stock options with an exercise price of $0.76.

Director Don M. Hardison was granted 10,000 stock options in MDxHealth SA as part of a standard equity compensation arrangement.

MDxHealth VP of Finance and Accounting Brendan O'Connell was granted 100,000 stock options with an exercise price of $0.76.

CEO Michael McGarrity was granted 942,200 share options in MDxHealth SA as part of a compensation package.

Director Hilde Windels was granted 10,000 stock options in MDxHealth SA as part of a standard equity compensation arrangement.

MDxHealth Chief Commercial Officer John Bellano was granted 333,000 stock options with an exercise price of $0.76.

Bleichroeder LP has disclosed a beneficial ownership of 31,648,563 ordinary shares, representing 33.2% of MDxHealth SA, acquired through a registered direct offering.

Laurence W. Lytton has reported a beneficial ownership of 9.6% in MDxHealth SA's ordinary shares.

AWM Investment Company, Inc. has filed a Schedule 13G amendment, reporting zero beneficial ownership of MDxHealth SA common stock as of June 30, 2026.

Exact Sciences Corporation and its subsidiary, Genomic Health, Inc., have reported a 12.0% beneficial ownership stake in MDxHealth SA ordinary shares.

Laurence W. Lytton has filed an amended Schedule 13G, reporting beneficial ownership of 6.4% of MDxHealth SA's Ordinary Shares as of September 30, 2025.

Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach have jointly disclosed a 15% beneficial ownership stake in MDxHealth SA, holding 7,429,609 ordinary shares.

Bleichroeder LP and Bleichroeder Holdings LLC have filed an amendment to their Schedule 13G, confirming their beneficial ownership of 14.9% of MDxHealth SA's Ordinary Shares as of December 31, 2024.